Akebia Therapeutics, Inc. (AKBA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
AKBA currently has 267M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 25.26% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 267.0M shares outstanding |
270M | 0 |
| Nov 10, 2025 |
10-Q filing | 264.8M shares outstanding |
260M | 0 |
| Aug 07, 2025 |
10-Q filing | 262.6M shares outstanding |
260M | 0 |
| May 08, 2025 |
10-Q filing | 241.6M shares outstanding |
240M | 0 |
| Mar 13, 2025 |
10-K filing | 236.2M shares outstanding |
240M | 0 |
| Feb 07, 2025 |
8-K filing: Akebia Therapeutics, Inc. issued a warrant to Kreos Capital VII Aggregator SCSp to purchase 1,153,846 shares of the Company's common stock at an exercise price of $1.30 per share in connection with the drawdown of the Extended Tranche C Loan. |
210M | 12M |
| Nov 07, 2024 |
10-Q filing | 210.3M shares outstanding |
210M | 12M |
| Sep 03, 2024 |
S-3 filing: Akebia Therapeutics, Inc. is offering shares of its common stock having an aggregate offering price of up to $75,000,000 through an "at the market offering" via sales agent Jefferies LLC, with the intention to use the net proceeds for general corporate purposes. |
210M | 13M |
| Aug 08, 2024 |
10-Q filing | 209.7M shares outstanding |
210M | 0 |
| May 09, 2024 |
10-Q filing | 205.0M shares outstanding |
200M | 0 |
| Mar 14, 2024 |
10-K filing | 209.4M shares outstanding |
210M | 0 |
| Nov 08, 2023 |
10-Q filing | 188.3M shares outstanding |
190M | 0 |
| Aug 28, 2023 |
10-Q filing | 186.8M shares outstanding |
190M | 0 |
| May 08, 2023 |
10-Q filing | 184.8M shares outstanding |
180M | 0 |
| Mar 10, 2023 |
10-K filing | 182.8M shares outstanding |
180M | 0 |
| Nov 03, 2022 |
10-Q filing | 183.9M shares outstanding |
180M | 0 |
| Aug 04, 2022 |
10-Q filing | 183.6M shares outstanding |
180M | 0 |
| May 09, 2022 |
10-Q filing | 179.6M shares outstanding |
180M | 0 |
| Mar 01, 2022 |
10-K filing | 165.9M shares outstanding |
170M | 7.8M |
| Mar 01, 2022 |
POS AM filing: Akebia Therapeutics, Inc. is offering debt securities, common stock and preferred stock up to $300,000,000 in the aggregate from time to time in one or more offerings. |
170M | 0 |
| Nov 04, 2021 |
10-Q filing | 173.8M shares outstanding |
170M | 0 |
| Aug 05, 2021 |
10-Q filing | 174.5M shares outstanding |
170M | 0 |
| May 10, 2021 |
10-Q filing | 160.1M shares outstanding |
160M | 0 |
| Feb 25, 2021 |
10-K filing | 153.5M shares outstanding |
150M | 0 |
| Nov 05, 2020 |
10-Q filing | 144.5M shares outstanding |
140M | 0 |
| Aug 10, 2020 |
10-Q filing | 143.3M shares outstanding |
140M | 0 |
| May 05, 2020 |
10-Q filing | 130.3M shares outstanding |
130M | 0 |
| Mar 12, 2020 |
10-K filing | 129.9M shares outstanding |
130M | 0 |